Navigation Links
deCODE Discovers Four New Risk Factors for Prostate Cancer
Date:9/20/2009

REYKJAVIK, Iceland, September 20 /PRNewswire-FirstCall/ --

- Findings Further Increase Power of DNA-Based Testing to Identify Men at Substantially Increased Risk, and Will be Integrated Into the deCODE ProstateCancer(TM) Test

deCODE genetics (Nasdaq: DCGN) today announced that a team of its scientists and academic colleagues from Finland, Spain, the Netherlands and the United States have today published the discovery of four novel single-letter variations in the sequence of the human genome (SNPs) conferring increased risk of prostate cancer. This is the sixth set of risk factors for prostate cancer that deCODE has found. The SNPs are located on chromosomes 3q21, 19q13, as well as on 8q24, a region of the genome where deCODE and others have previously discovered risk factors for prostate, breast, colon and bladder cancer. The deCODE team followed up these latest findings with a population-based analysis in Iceland of these and other published sequence variants linked to risk of prostate cancer. This analysis demonstrates that by testing for these published SNPs it is possible to identify the approximately 1.5% of men who are at more than 2.5 times the average risk of the disease.

"With these latest findings we continue to extend our understanding of the genetic risk factors for prostate cancer, the second most common cause of cancer deaths in men. Using our ability to put these SNPs in a population-wide context, we show that it is now possible to identify those who are at more than 30% lifetime risk, independent of other standard risk factors such as age and family history. By incorporating this new, personalized gauge of susceptibility into our arsenal for improving prevention and early diagnosis, we can more effectively and accurately identify those men who would benef
'/>"/>

SOURCE DeCODE Genetics Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke
2. deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia
3. deCODE Receives California Clinical Laboratory License
4. deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention
5. A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer
6. Major deCODE-led Study Underscores Role of the Brain in Obesity
7. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders
8. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
9. deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia
10. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
11. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today it has completed enrollment of the ... Committee (DRC) earlier this year, into the company,s ... first-in-class innate defense regulator (IDR) and is being ...
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
... , HELSINKI, Dec. 14 Cancer ... with the introduction of RapidArc® radiotherapy technology from Varian Medical ... radiotherapy clinic in the Nordic region. Clinicians at Docrates Clinic ... radiotherapy to treat patients with multiple brain metastases and cancers ...
... , WALTHAM, Mass., Dec. ... authority on medical technology market intelligence, increased use of safety ... be a key driver of the enteral feeding device markets ... and European Markets for Enteral Feeding Devices 2010 report ...
Cached Medicine Technology:Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3
(Date:8/31/2015)... ... , ... Cosmetic Town Journal is an online plastic surgery ... successful cosmetic procedure; from publishing encyclopedic medical articles to inform patients and connecting ... help. , It is clear that the Cosmetic Town aesthetic surgery community has ...
(Date:8/31/2015)... ... August 31, 2015 , ... Southern Vacation Rentals – a member of ... fellow South Walton property management company, 360 Blue, in support of the ... of the world. The two companies will collect any unopened food items left in ...
(Date:8/31/2015)... ... 2015 , ... India Network Foundation, a non-profit US-based sponsor ... summarizes all available plans, plan maximums, pre-existing condition coverage limits and deductible in ... Network members make an informed decision regarding the care they want for their ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... management program that is unique to the Lake Orion area. This program is ... County. , WEmovestrong’s weight management program will incorporate group fitness and nutritional ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... President, Marketing and Corporate Communications. In this capacity, Michael will provide strategic leadership ... an industry leader in consumer-focused programs that have contributed to the company’s rapid ...
Breaking Medicine News(10 mins):Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:CareSource Names Vice President, Marketing and Corporate Communications 2
... Research finds that for most adults in the Framingham ... mass index (BMI). However, for 13 percent// of the ... apolipoprotein A5 gene (APOA5), higher dietary fat was not ... and colleagues analyzed several common gene variants known as ...
... be a mantra to stay fit. New research suggests ... lifespan. ,Researchers at the University of Copenhagen ... of commonly used vitamin supplements, including vitamins A, E ... found that vitamin supplements appeared to raise, not lower, ...
... Olympics next year, Beijing has reserved many hospital beds for emergency ... outbreak. ,Beijing has planned to keep at least 6,350 ... infectious diseases like bird flu and SARS. ,China has ... bird flu. As a preventive measure, China took the intelligent step ...
... new analysis of both estrogen and estrogen plus progestin shows ... events in women starting// hormone therapy less than 10 years ... Yale and eight other study centers participating in the Kronos ... reduction in overall deaths among women aged 50 to 59 ...
... Davidson, 45, was basking in the happiness of her 27th ... she began to suffer// hot flashes, she dismissed them as ... but didn’t think so even in her wildest dreams. The ... symptoms of advancing menopause. At one instance, when she was ...
... study provides evidence that racial differences in the clinical ... to biological factors rather than differences in access to ... in a managed health care system found that in ... at significantly higher risk for being diagnosed with more ...
Cached Medicine News:Health News:Study Finds Dietary Fat Interacts With Genes 2Health News:Study Finds Dietary Fat Interacts With Genes 3Health News:Early Estrogen Therapy May Reduce Cardiovascular Risks 2Health News:More Aggressive Breast Cancer in Hispanics Independent of Health Care Utilization 2
... Splint is constructed of a durable heat moldable ... flexor tendons of the hand and fingers from ... in the later stages of the healing process. ... hand and positions the wrist at 30° of ...
Bunell Mini-Modified Safety Finger Pin reduces PIP flexion contractures....
... FoamWrap Finger Trappers are ideal for ... restore finger motion. Finger Trappers' non-slip foam ... place the fingers in traction. These are ... size. Sold in packages of 5 and ...
... physiological causes of minor knee pain like ... in concert with the motion of the ... and patellar tendon and assisting in the ... plastic support with high density foam padding ...
Medicine Products: